List view / Grid view
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
4 January 2016 | By Victoria White
The updated canSAR database will allow scientists working in the UK and across the globe to design new cancer treatments more effectively...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
4 January 2016 | By Victoria White
As part of the collaboration agreement, Symphogen is to receive $175 million upfront, in addition to potential future milestone payments and royalties...
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
23 December 2015 | By Victoria White
A team at CSHL has announced preclinical data suggesting the promise of a novel drug directed against a novel target in malignant mammary tumours...
23 December 2015 | By Victoria White
ARA 290 is a first-in-class synthetic peptide designed to activate the innate repair mechanism in the setting of tissue injury...
22 December 2015 | By Victoria White
MDSCs are immune cells that “expand” when faced with cancer, inflammation or infections, giving them the unique ability to suppress the body’s T-cell response to disease...
22 December 2015 | By Victoria White
A study suggests that enhancing proteasome activity with drugs during the early stages of Alzheimer’s may prevent dementia and reduce damage to the brain...
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
22 December 2015 | By Victoria White
The funding is awarded in the context of the Neuratect CRACK IT Challenge to support development of better predictive, high-throughput, animal-free models for neurotoxicity of medicines and chemicals...
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
21 December 2015 | By Victoria White
Their goal is to develop a therapeutic vaccine which aims to intercept HPV infection-related disease, particularly in those who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer...
18 December 2015 | By Victoria White
Variant says VAR 200 has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney, including focal segmental glomerulosclerosis...
